Compugen Reports Strong FY2025 Results, Secures $65M Non-Dilutive Funding, Extends Cash Runway to 2029
CGEN sits 66% above its 52-week low of $1.13.
Summary
Compugen Ltd. reported a significant financial turnaround in fiscal year 2025, achieving net profit and substantially increasing its cash position, bolstered by a $65 million non-dilutive payment from AstraZeneca, extending its cash runway into 2029.
Key Events · Earnings and Guidance · CGEN
-
Strong Financial Performance
Compugen achieved a net profit of $35.3 million in 2025, a significant improvement from net losses of $14.2 million in 2024 and $18.8 million in 2023. Revenues increased substantially to $72.8 million in 2025 from $27.9 million in 2024.
-
Secured $65M Non-Dilutive Funding
The company received a $65 million upfront payment in December 2025 from AstraZeneca by selling a portion of its existing royalty interest in rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 program.
-
Extended Cash Runway
Compugen projects its current cash, cash equivalents, short-term bank deposits, and marketable securities will be sufficient to fund operations into 2029, without considering additional financing.
-
TIGIT Program (COM902) Update
Due to recent negative data in the broader TIGIT field, the company believes its COM902 program has limited near-term value and does not plan to initiate new clinical trials for this anti-TIGIT antibody.
Analysis · CGEN · Life Sciences
Compugen Ltd. reported a significant financial turnaround for fiscal year 2025, achieving a net profit of $35.3 million compared to losses in previous years, with revenues climbing to $72.8 million. This strong performance was significantly bolstered by a $65 million upfront payment received in December 2025 from AstraZeneca, stemming from an amendment to their license agreement where Compugen sold a portion of its future royalty interest in rilvegostomig. This non-dilutive capital infusion, representing a substantial portion of the company's market capitalization, has extended Compugen's cash runway into 2029, significantly de-risking its near-term financing needs. While the company announced a decision not to initiate new clinical trials for its COM902 (anti-TIGIT antibody) program due to recent negative data in the broader TIGIT field, it continues to advance other key clinical programs, including COM701 (anti-PVRIG antibody) in a blinded randomized ovarian cancer trial and GS-0321 (anti-IL-18 binding protein antibody) under a license with Gilead. The filing also notes the company's belief that it was classified as a Passive Foreign Investment Company (PFIC) for 2025, which has adverse U.S. federal income tax consequences for U.S. shareholders, and details ongoing geopolitical risks in Israel. This comprehensive annual report follows a 6-K filing on the same day that provided preliminary financial results, adding substantial detail and context to the previously announced figures.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGEN was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.3M. The 52-week trading range was $1.13 to $2.38. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.